Asceneuron is a Swiss biotechnology company focused on developing small molecule therapeutics targeting tau pathology in Alzheimer's disease and other neurodegenerative disorders. The company's lead program, ASN51, is a novel tau aggregation inhibitor that represents a differentiated approach to addressing tau pathology, which correlates strongly with cognitive decline in AD patients[@asceneuron].
Technology Platform
Asceneuron's platform focuses on:
Tau Aggregation Inhibition: Targeting the formation of toxic tau aggregates
Small Molecule CNS Delivery: Optimized brain-penetrant compounds
Tau Pathology Modification: Disease-modifying approach rather than symptomatic relief
Pipeline
ASN51 (Lead Program)
| Attribute | Details | |-----------|---------| | Mechanism | Tau aggregation inhibitor | | Target | Pathological tau species | | Indication | Alzheimer's disease | | Stage | Phase 1/2 | | Trial ID | NCT04759365 |
Clinical Development:
Phase 1 study in healthy young adult, elderly subjects, and AD patients (completed 2022)
Phase 2 study in early AD patients (started October 2024)
Asceneuron is a Swiss biotechnology company focused on developing small molecule therapeutics targeting tau pathology in Alzheimer's disease and other neurodegenerative disorders. The company's lead program, ASN51, is a novel tau aggregation inhibitor that represents a differentiated approach to addressing tau pathology, which correlates strongly with cognitive decline in AD patients[@asceneuron].
Technology Platform
Asceneuron's platform focuses on:
Tau Aggregation Inhibition: Targeting the formation of toxic tau aggregates
Small Molecule CNS Delivery: Optimized brain-penetrant compounds
Tau Pathology Modification: Disease-modifying approach rather than symptomatic relief
Pipeline
ASN51 (Lead Program)
| Attribute | Details | |-----------|---------| | Mechanism | Tau aggregation inhibitor | | Target | Pathological tau species | | Indication | Alzheimer's disease | | Stage | Phase 1/2 | | Trial ID | NCT04759365 |
Clinical Development:
Phase 1 study in healthy young adult, elderly subjects, and AD patients (completed 2022)
Phase 2 study in early AD patients (started October 2024)
Tau aggregation inhibitors target the pathological accumulation of tau protein into neurofibrillary tangles (NFTs), which are a hallmark of Alzheimer's disease and several other dementias. Unlike antibody approaches that target extracellular tau, small molecule inhibitors can potentially:
Penetrate the blood-brain barrier more effectively
Target intracellular tau aggregation
Modulate tau seeding and propagation
Potentially modify disease progression
Clinical Trial Data
Phase 1 Study (NCT04759365)
Title: Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
Status: Completed
Enrollment: 25 subjects
Start Date: June 2021
Completion: August 2022
Objectives:
Evaluate safety and tolerability
Characterize pharmacokinetics
Assess pharmacodynamic markers
Phase 2 Study (NCT06612599)
Title: Study of ASN51 in Adults With Early Alzheimer's Disease
Status: Terminated
Enrollment: 123 subjects
Start Date: October 2024
Completion: November 2024
Scientific Rationale
Tau pathology correlates more strongly with cognitive impairment than amyloid plaques, making tau aggregation an attractive therapeutic target:
Neurofibrillary tangles form inside neurons and disrupt cellular function
Tau spread follows a predictable pattern in AD brain, correlating with disease progression
Tau aggregation precedes clinical symptoms in many cases
Tau inhibition could potentially slow or halt disease progression
Competitive Landscape
Asceneuron's tau aggregation inhibitor approach competes with: